Shared on 31 Oct 25
Fair value Decreased 4.17%Avantor’s analyst price target has been reduced from $14.40 to $13.80 per share, as analysts cite ongoing operational headwinds and limited near-term earnings visibility following recent downgrades and mixed guidance. Analyst Commentary Recent analyst notes on Avantor capture a divided outlook, reflecting both positive updates from some firms and notable caution from others as the company contends with ongoing operational challenges.
Shared on 16 Oct 25
Fair value Increased 2.00%Pharma Contracts And R&D Will Drive Growth Amid Price Pressures
Analysts have modestly increased their price target for Avantor, raising it by $0.28 to $14.40. They cite revised expectations for end market recovery and alignment with company outlooks.
Shared on 04 Aug 25
Fair value Decreased 18%Pharma Contracts And R&D Will Drive Growth Amid Price Pressures
The consensus analyst price target for Avantor has been significantly reduced, primarily due to notable declines in both revenue growth forecasts and net profit margin expectations, resulting in a new fair value estimate of $14.12. What's in the News Emmanuel Ligner appointed President and CEO, succeeding Michael Stubblefield; Ligner brings extensive life sciences leadership experience from GE Life Sciences, Cytiva, and Cerba HealthCare.
Shared on 07 May 25
Fair value Increased 1.10%Lab Solutions And AI E-commerce Will Streamline Operations
Shared on 30 Apr 25
Fair value Decreased 23%Lab Solutions And AI E-commerce Will Streamline Operations
AnalystConsensusTarget has increased revenue growth from 2.5% to 3.0% and decreased profit margin from 9.6% to 8.0%.
Shared on 23 Apr 25
Fair value Decreased 0.90%Lab Solutions And AI E-commerce Will Streamline Operations
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 16 Apr 25
Fair value Increased 31%Lab Solutions And AI E-commerce Will Streamline Operations
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 09 Apr 25
Fair value Decreased 29%Lab Solutions And AI E-commerce Will Streamline Operations
Shared on 02 Apr 25
Fair value Decreased 1.96%Lab Solutions And AI E-commerce Will Streamline Operations
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 26 Mar 25
Lab Solutions And AI E-commerce Will Streamline Operations
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 19 Mar 25
Fair value Decreased 0.65%Lab Solutions And AI E-commerce Will Streamline Operations
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 10 Mar 25
Fair value Increased 43%Lab Solutions And AI E-commerce Will Streamline Operations
AnalystConsensusTarget has decreased revenue growth from 2.9% to 2.4%.